Market Place
Sourcing Support
2 eye disease biotechs merge, set sights on FDA approval
12 Dec 2024 //
FIERCE BIOTECH
Visus Therapeutics to Present at 2023 JMP Securities Life Science Conference
12 May 2023 //
BUSINESSWIRE
Visus Announces Positive Topline Clinical Data from Ph3 Pivotal BRIO-I Trial
20 Apr 2023 //
BUSINESSWIRE
Visus Therapeutics Announces New Scientific Data to Be Presented During the 2023
19 Apr 2023 //
BUSINESSWIRE
Visus Appoints Industry Expert Jehan Tamboowalla to Senior VP
12 Apr 2023 //
BUSINESSWIRE
Visus Completes Enrollment in BRIO-I, a Phase 3 Clinical Trial of BRIMOCHOL PF
22 Mar 2023 //
BUSINESSWIRE
Visus Therapeutics to Attend TD Cowen’s 43rd Annual Health Care Conference
02 Mar 2023 //
BUSINESSWIRE
Visus Therapeutics Appoints Eric D. Donnenfeld, M.D., to Board of Directors
11 Jan 2023 //
BUSINESSWIRE
Visus Expands its Portfolio With Acquisition of ViewPoint`s Assets
28 Sep 2022 //
BUSINESSWIRE
Visus Therapeutics to Present at the Baird 2022 Global Healthcare Conference
07 Sep 2022 //
BUSINESSWIRE
Visus & Zhaoke Enter Excl. Licensing Agreement for BRIMOCHOL PF, Carbachol PF
11 May 2022 //
BUSINESSWIRE
Visus Tx Announces New Scientific Data to Be Presented During the 2022 ARVO
27 Apr 2022 //
BUSINESSWIRE
Visus Tx Initiates Phase 3 Pivotal Trials of BRIMOCHOL PF for Presbyopia
22 Mar 2022 //
BUSINESSWIRE
Visus Tx says Appoints of Eye Care Industry Veteran Julia Williams as VP
16 Mar 2022 //
BUSINESSWIRE
Visus Therapeutics to Host Capital Markets Day Tomorrow August 31, 2021
30 Aug 2021 //
BUSINESSWIRE
Visus Therapeutics Appoints Industry Leaders T. Valorie and D. Moxie
25 Aug 2021 //
BUSINESSWIRE
Visus, with one drug chasing AbbVie, inks deals to grow pipeline
20 Aug 2021 //
FIERCEBIOTECH
Visus Therapeutics secures license and expands ophthalmic drug portfolio.
19 Aug 2021 //
BUSINESSWIRE
Visus Secures $20 Million in Additional Financing Led by New Investor LSP
10 Aug 2021 //
BUSINESSWIRE
Visus Therapeutics to Host First Capital Markets Day in New York City
05 Aug 2021 //
BUSINESSWIRE
Visus Therapeutics Announces Executive Leadership Appointments in Operations
15 Jun 2021 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.